➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Mallinckrodt
AstraZeneca
Moodys
McKesson

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Patent: 10,125,398

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,125,398
Title:Compositions and methods for the diagnosis and treatment of bone fractures and disorders
Abstract: The present invention relates to the therapy, prophylaxis and diagnosis of disorders that are associated with aberrant bone mineral density, in particular osteoporosis; wherein the level of selected micro RNAs in samples of patients are detected and wherein an increase or decrease of said level compared to the level of healthy individuals is indicative of the disorder.
Inventor(s): Grillari; Johannes (Bisamberg, AT), Grillari; Regina (Bisamberg, AT), Hackl; Matthias (Vienna, AT), Schraml; Elisabeth (Vienna, AT), Weilner; Sylvia (Perzendorf, AT)
Assignee: UNIVERSITAT FUR BODENKULTUR WIEN (Vienna, AT)
Application Number:15/318,646
Patent Claims:see list of patent claims

Details for Patent 10,125,398

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen PROLIA denosumab INJECTABLE; SUBCUTANEOUS 125320 001 2010-06-01   Start Trial UNIVERSITAT FUR BODENKULTUR WIEN (Vienna, AT) 2034-06-13 RX Orphan search
Amgen XGEVA denosumab INJECTABLE; SUBCUTANEOUS 125320 002 2010-06-01   Start Trial UNIVERSITAT FUR BODENKULTUR WIEN (Vienna, AT) 2034-06-13 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Express Scripts
Harvard Business School
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.